AbCellera Biologics (ABCL) Return on Capital Employed (2021 - 2026)

AbCellera Biologics has reported Return on Capital Employed for 6 years, with the latest figure at 16.5% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 876.0% year-over-year to 16.5%; the trailing twelve-month figure through Mar 2026 stood at 16.5% (up 876.0% YoY), and the FY2025 full-year result was 16.77%, up 658.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 16.5%, up from 16.8% in the prior quarter.
• The five-year high for Return on Capital Employed was 22.89% in Q3 2022, with the low at 25.26% in Q1 2025.
• Historically, Return on Capital Employed has averaged 8.79% across 5 years, with a median of 16.58% in 2024.
• Annual changes were most pronounced in 2023 — Return on Capital Employed slumped 3766 bps — and 2026, when it surged 876 bps.
• AbCellera Biologics' Return on Capital Employed stood at 15.16% in 2022, then sank by 213 bps to 17.17% in 2023, then plunged by 41 bps to 24.21% in 2024, then surged by 31 bps to 16.8% in 2025, then grew by 2 bps to 16.5% in 2026.
• The last three Return on Capital Employed figures came in at 16.5% (Q1 2026), 16.8% (Q4 2025), and 19.94% (Q3 2025), per Business Quant data.